Real World Study of MPM in China

• Conditions: Treatments; Diagnoses Disease; Malignant Pleural Mesothelioma; Prognosis

• Registration Number: NCT05042557
• Lead Sponsor: Chinese Academy of Medical Sciences

Brief Summary

Malignant pleural mesothelioma (MPM) is a highly aggressive tumor with atypical clinical manifestations. Most patients with MPM are at an advanced stage at the time of diagnosis, and only a few patients can be cured by radical surgery and other treatment measures. Pemetrexed + cisplatin chemotherapy with or without bevacizumab is still the standard treatment for MPM. In recent years, multimodality therapy including surgery, radiotherapy and chemotherapy have shown certain advantages in improving patient overall survival time. Targeted and immunotherapy may bring breakthroughs in MPM therapy. However, there are still no high-quality evidence-based medical evidence reports on the treatment model and effects of MPM patients in China.

Focusing on MPM, we plan to systematically review the relevant scientific literature, confirm relevant scientific research questions, and provide references for related treatments. On this basis, we will estimate MPM incidence and mortality rates from 2014 to 2025 based on the data published by the National Cancer Registry. Meanwhile, a retrospective study cohort was constructed based on the electronic medical record database, and according to the research demand, patients were followed up with their post-discharge survival status to comprehensively describe and analyze the incidence, diagnosis, treatment, and prognosis of MPM patients. Also, exploratory analysis of the therapeutic effects of existing clinical treatments was conducted.

Detailed Description

Not available

Study Timeline

• Study Start: 2021-06-01
• Status Verified: 2021-09
• Study First Submitted: 2021-09-05
• Study First Submitted QC: 2021-09-05
• Last Update Submitted: 2021-09-05
• Study First Posted: 2021-09-13
• Last Update Posted: 2021-09-13
• Primary Completion: 2022-06-01
• Study Completion: 2022-12-20

Recruitment & Eligibility

• Status: UNKNOWN
• Sex: All
• Target Recruitment: 500

Inclusion Criteria

• Pathologically confirmed as malignant pleural mesothelioma
• Aged over 18

Exclusion Criteria

• Follow-up less than 3 months

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Overall survival	2-year overall survival	Overall survival is defined as the time from diagnosis to death for any reason or last follow-up

Secondary Outcome Measures

Name	Time	Method
Progression-free survival	2-year progression-free survival	Progression-free survival is defined as the time from diagnosis to the first event of progression

Trial Locations

Locations (1)

National Cancer Center/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College; 🇨🇳 Beijing, China